Tapentadol is partly metabolized with the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medicines that enhance or repress the action/expression of a number of of these enzymes, and also with substrates of these enzymes (as a consequence of Level of competition to the enzyme); some enzyme mediators/substrates requi